Stephanie M. W. Y. van de Ven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stephanie M. W. Y. van de Ven has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
Marjolein van der Voort
Minimally Invasive Healthcare Group, Philips Research, High Tech Campus 34, 5656AE Eindhoven, the Netherlands
7 shared publicationsBernhard Brendel
Philips Research Europe, Eindhoven, The Netherlands
6 shared publicationsLeon Bakker
Philips Research Europe, Eindhoven, The Netherlands
6 shared publicationsPeter Luijten
Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands
6 shared publicationsTim Nielsen
Philips Research Europe, Eindhoven, The Netherlands
6 shared publicationsAndrea Wiethoff
Philips Healthcare, Best, the Netherlands
5 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (11) , 32-39
Clinical Utility of [18F]Fluoroestradiol PET/CT to Guide Second Line Treatment Decision in ER-Positive HER2-Negative Metastatic Breast Cancer After Progression on First Line Endocrine Therapy
- 18 September 2026
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (11) , 32-39
Open AccessClinical Utility of [18F]Fluoroestradiol PET/CT to Guide Second Line Treatment Decision in ER-Positive HER2-Negative Metastatic Breast Cancer After Progression on First Line Endocrine Therapy
- Open Access
- 6 July 2026
- Published by Elsevier in SSRN Electronic Journal
Clinical utility of [18F]fluoroestradiol PET/CT to guide second line treatment decision in ER-positive HER2-negative metastatic breast cancer after progression on first line endocrine therapy
PURPOSE: Many patients with ER-positive HER2-negative metastatic breast cancer (MBC) derive limited benefit from second line endocrine therapy. This study evaluated the impact of [18F]fluoroestradiol (FES) PET/CT on second line therapeutic decision-making.METHODS: Patients with progression of ER-positive HER2-negative MBC on first line endocrine therapy were prospectively enrolled in 17 U.S. centers to undergo [18F]FES PET/CT after standard-of-care (SoC) imaging. [18F]FES uptake in MBC lesions was evaluated. Treating oncologists completed questionnaires before and after [18F]FES PET/CT, detailing therapeutic decisions plus their confidence in the decisions. The primary endpoint was the proportion of patients whose therapeutic management changed after [18F]FES PET/CT.RESULTS: Between January 2023 and May 2024, 45 patients underwent [18F]FES PET/CT. Imaging results led to management changes in 17 patients (37.8%; 95% CI 23.8% - 53.5%). Twenty-five patients avoided further diagnostic testing, while 7 patients received additional tests. Oncologist’s confidence in second line treatment decision increased on average from 6.6 before [18F]FES PET/CT to 8.6 afterward on a ten-point scale (p <0.0001). In 25 patients (55.6%), lesions visible on SoC imaging were reported as “absent” (FES-negative) on [18F]FES PET/CT, suggesting potential loss or downregulation of ER that functionally binds estrogen.CONCLUSION: [18F]FES PET/CT altered therapeutic management in 37.8% of patients with MBC progressing on first line endocrine therapy and significantly increased oncologist’s confidence in treatment selection. This imaging modality could help prevent unnecessary prolongation of ineffective endocrine therapy and delays in initiation of more effective options. Future studies should investigate potential outcome benefits after [18F]FES PET/CT-informed management changes.
- 6 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessClinical utility of [18F]fluoroestradiol PET/CT to guide second line treatment decision in ER-positive HER2-negative metastatic breast cancer after progression on first line endocrine therapy
PURPOSE: Many patients with ER-positive HER2-negative metastatic breast cancer (MBC) derive limited benefit from second line endocrine therapy. This study evaluated the impact of [18F]fluoroestradiol (FES) PET/CT on second line therapeutic decision-making.METHODS: Patients with progression of ER-positive HER2-negative MBC on first line endocrine therapy were prospectively enrolled in 17 U.S. centers to undergo [18F]FES PET/CT after standard-of-care (SoC) imaging. [18F]FES uptake in MBC lesions was evaluated. Treating oncologists completed questionnaires before and after [18F]FES PET/CT, detailing therapeutic decisions plus their confidence in the decisions. The primary endpoint was the proportion of patients whose therapeutic management changed after [18F]FES PET/CT.RESULTS: Between January 2023 and May 2024, 45 patients underwent [18F]FES PET/CT. Imaging results led to management changes in 17 patients (37.8%; 95% CI 23.8% - 53.5%). Twenty-five patients avoided further diagnostic testing, while 7 patients received additional tests. Oncologist’s confidence in second line treatment decision increased on average from 6.6 before [18F]FES PET/CT to 8.6 afterward on a ten-point scale (p <0.0001). In 25 patients (55.6%), lesions visible on SoC imaging were reported as “absent” (FES-negative) on [18F]FES PET/CT, suggesting potential loss or downregulation of ER that functionally binds estrogen.CONCLUSION: [18F]FES PET/CT altered therapeutic management in 37.8% of patients with MBC progressing on first line endocrine therapy and significantly increased oncologist’s confidence in treatment selection. This imaging modality could help prevent unnecessary prolongation of ineffective endocrine therapy and delays in initiation of more effective options. Future studies should investigate potential outcome benefits after [18F]FES PET/CT-informed management changes.
- 11 May 2016
- Published by Wiley in Proteomics
- Vol. 16 (11-12) , 1660-1669
Protein biomarkers on tissue as imaged via MALDI mass spectrometry: A systematic approach to study the limits of detection
MALDI mass spectrometry imaging (MSI) is emerging as a tool for protein and peptide imaging across tissue sections. Despite extensive study, there does not yet exist a baseline study evaluating the potential capabilities for this technique to detect diverse proteins in tissue sections. In this study, we developed a systematic approach for characterizing MALDI‐MSI workflows in terms of limits of detection, coefficients of variation, spatial resolution, and the identification of endogenous tissue proteins. Our goal was to quantify these figures of merit for a number of different proteins and peptides, in order to gain more insight in the feasibility of protein biomarker discovery efforts using this technique. Control proteins and peptides were deposited in serial dilutions on thinly sectioned mouse xenograft tissue. Using our experimental setup, coefficients of variation were <30% on tissue sections and spatial resolution was 200 μm (or greater). Limits of detection for proteins and peptides on tissue were in the micromolar to millimolar range. Protein identification was only possible for proteins present in high abundance in the tissue. These results provide a baseline for the application of MALDI‐MSI towards the discovery of new candidate biomarkers and a new benchmarking strategy that can be used for comparing diverse MALDI‐MSI workflows.
- 11 May 2016
- Published by Wiley in Proteomics
- Vol. 16 (11-12) , 1660-1669
Protein biomarkers on tissue as imaged via MALDI mass spectrometry: A systematic approach to study the limits of detection
MALDI mass spectrometry imaging (MSI) is emerging as a tool for protein and peptide imaging across tissue sections. Despite extensive study, there does not yet exist a baseline study evaluating the potential capabilities for this technique to detect diverse proteins in tissue sections. In this study, we developed a systematic approach for characterizing MALDI‐MSI workflows in terms of limits of detection, coefficients of variation, spatial resolution, and the identification of endogenous tissue proteins. Our goal was to quantify these figures of merit for a number of different proteins and peptides, in order to gain more insight in the feasibility of protein biomarker discovery efforts using this technique. Control proteins and peptides were deposited in serial dilutions on thinly sectioned mouse xenograft tissue. Using our experimental setup, coefficients of variation were <30% on tissue sections and spatial resolution was 200 μm (or greater). Limits of detection for proteins and peptides on tissue were in the micromolar to millimolar range. Protein identification was only possible for proteins present in high abundance in the tissue. These results provide a baseline for the application of MALDI‐MSI towards the discovery of new candidate biomarkers and a new benchmarking strategy that can be used for comparing diverse MALDI‐MSI workflows.
- Open Access
- 1 May 2016
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 15 (5) , 1761-1772
Probabilistic Segmentation of Mass Spectrometry (MS) Images Helps Select Important Ions and Characterize Confidence in the Resulting Segments
- 1 May 2016
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 15 (5) , 1761-1772
Open AccessProbabilistic Segmentation of Mass Spectrometry (MS) Images Helps Select Important Ions and Characterize Confidence in the Resulting Segments
- Open Access
- 15 March 2015
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 31 (14) , 2418-2420
Cardinal: an R package for statistical analysis of mass spectrometry-based imaging experiments
Cardinal is an R package for statistical analysis of mass spectrometry-based imaging (MSI) experiments of biological samples such as tissues. Cardinal supports both Matrix-Assisted Laser Desorption/Ionization (MALDI) and Desorption Electrospray Ionization-based MSI workflows, and experiments with multiple tissues and complex designs. The main analytical functionalities include (1) image segmentation, which partitions a tissue into regions of homogeneous chemical composition, selects the number of segments and the subset of informative ions, and characterizes the associated uncertainty and (2) image classification, which assigns locations on the tissue to pre-defined classes, selects the subset of informative ions, and estimates the resulting classification error by (cross-) validation. The statistical methods are based on mixture modeling and regularization. Contact: o.vitek@neu.edu Availability and implementation: The code, the documentation, and examples are available open-source at www.cardinalmsi.org under the Artistic-2.0 license. The package is available at www.bioconductor.org.
- 15 March 2015
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 31 (14) , 2418-2420
Open AccessCardinal: an R package for statistical analysis of mass spectrometry-based imaging experiments
Cardinal is an R package for statistical analysis of mass spectrometry-based imaging (MSI) experiments of biological samples such as tissues. Cardinal supports both Matrix-Assisted Laser Desorption/Ionization (MALDI) and Desorption Electrospray Ionization-based MSI workflows, and experiments with multiple tissues and complex designs. The main analytical functionalities include (1) image segmentation, which partitions a tissue into regions of homogeneous chemical composition, selects the number of segments and the subset of informative ions, and characterizes the associated uncertainty and (2) image classification, which assigns locations on the tissue to pre-defined classes, selects the subset of informative ions, and estimates the resulting classification error by (cross-) validation. The statistical methods are based on mixture modeling and regularization. Contact: o.vitek@neu.edu Availability and implementation: The code, the documentation, and examples are available open-source at www.cardinalmsi.org under the Artistic-2.0 license. The package is available at www.bioconductor.org.
- Top Cited Papers
- 15 February 2014
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 74 (4) , 979-1004
Light In and Sound Out: Emerging Translational Strategies for Photoacoustic Imaging
Photoacoustic imaging (PAI) has the potential for real-time molecular imaging at high resolution and deep inside the tissue, using nonionizing radiation and not necessarily depending on exogenous imaging agents, making this technique very promising for a range of clinical applications. The fact that PAI systems can be made portable and compatible with existing imaging technologies favors clinical translation even more. The breadth of clinical applications in which photoacoustics could play a valuable role include: noninvasive imaging of the breast, sentinel lymph nodes, skin, thyroid, eye, prostate (transrectal), and ovaries (transvaginal); minimally invasive endoscopic imaging of gastrointestinal tract, bladder, and circulating tumor cells (in vivo flow cytometry); and intraoperative imaging for assessment of tumor margins and (lymph node) metastases. In this review, we describe the basics of PAI and its recent advances in biomedical research, followed by a discussion of strategies for clinical translation of the technique. Cancer Res; 74(4); 979–1004. ©2014 AACR.
- 15 February 2014
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 74 (4) , 979-1004
Top Cited PapersLight In and Sound Out: Emerging Translational Strategies for Photoacoustic Imaging
Photoacoustic imaging (PAI) has the potential for real-time molecular imaging at high resolution and deep inside the tissue, using nonionizing radiation and not necessarily depending on exogenous imaging agents, making this technique very promising for a range of clinical applications. The fact that PAI systems can be made portable and compatible with existing imaging technologies favors clinical translation even more. The breadth of clinical applications in which photoacoustics could play a valuable role include: noninvasive imaging of the breast, sentinel lymph nodes, skin, thyroid, eye, prostate (transrectal), and ovaries (transvaginal); minimally invasive endoscopic imaging of gastrointestinal tract, bladder, and circulating tumor cells (in vivo flow cytometry); and intraoperative imaging for assessment of tumor margins and (lymph node) metastases. In this review, we describe the basics of PAI and its recent advances in biomedical research, followed by a discussion of strategies for clinical translation of the technique. Cancer Res; 74(4); 979–1004. ©2014 AACR.
- 15 December 2013
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (24_Supplem) , P2-14
Abstract P2-14-03: Development and evaluation of a prediction model based on routine clinicopathological variables for predicting underestimated invasive breast cancer in women with ductal carcinoma in situ at stereotactic large core needle biopsy
Purpose: To develop a multivariable model for prediction of underestimated invasiveness in women with ductal carcinoma in situ (DCIS) at stereotactic large core needle biopsy (LCNB), that can be used to select patients for sentinel node biopsy (SNB) at primary surgery. Methods: From the literature, we selected potential preoperative predictors of underestimated invasive breast cancer. Data of patients with nonpalpable breast lesions who were diagnosed with DCIS at stereotactic LCNB, drawn from the COBRA (Core Biopsy after RAdiological localization) and COBRA2000 studies, were used to fit the multivariable model and assess its overall performance, discrimination, and calibration. Results: 348 women with LCNB-proven DCIS were available for analysis. In 100 (28.7%) patients invasive carcinoma was found at subsequent surgery. Nine predictors were included in the model. In the multivariable analysis, the predictors with the strongest association were lesion size (OR 1.12 per cm, 95% CI 0.98-1.28), the number of cores retrieved at biopsy (OR per core 0.87, 95% CI 0.75-1.01), presence of lobular cancerization (OR 5.29, 95% CI 1.25-26.77), and microinvasion (OR 3.75, 95% CI 1.42-9.87). The overall performance of the multivariable model was poor with an explained variation of 9% (Nagelkerke's R2), mediocre discrimination with area under the receiver operating characteristic curve of 0.66 (95% confidence interval 0.58-0.73), and fairly good calibration. Conclusion: The evaluation of our multivariable prediction model in a large, clinically representative study population, proves that routine clinical and pathological variables are not suitable to select patients with LCNB-proven DCIS for SNB during primary surgery. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-14-03.
- 15 December 2013
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (24_Supplem) , P2-14
Abstract P2-14-03: Development and evaluation of a prediction model based on routine clinicopathological variables for predicting underestimated invasive breast cancer in women with ductal carcinoma in situ at stereotactic large core needle biopsy
Purpose: To develop a multivariable model for prediction of underestimated invasiveness in women with ductal carcinoma in situ (DCIS) at stereotactic large core needle biopsy (LCNB), that can be used to select patients for sentinel node biopsy (SNB) at primary surgery. Methods: From the literature, we selected potential preoperative predictors of underestimated invasive breast cancer. Data of patients with nonpalpable breast lesions who were diagnosed with DCIS at stereotactic LCNB, drawn from the COBRA (Core Biopsy after RAdiological localization) and COBRA2000 studies, were used to fit the multivariable model and assess its overall performance, discrimination, and calibration. Results: 348 women with LCNB-proven DCIS were available for analysis. In 100 (28.7%) patients invasive carcinoma was found at subsequent surgery. Nine predictors were included in the model. In the multivariable analysis, the predictors with the strongest association were lesion size (OR 1.12 per cm, 95% CI 0.98-1.28), the number of cores retrieved at biopsy (OR per core 0.87, 95% CI 0.75-1.01), presence of lobular cancerization (OR 5.29, 95% CI 1.25-26.77), and microinvasion (OR 3.75, 95% CI 1.42-9.87). The overall performance of the multivariable model was poor with an explained variation of 9% (Nagelkerke's R2), mediocre discrimination with area under the receiver operating characteristic curve of 0.66 (95% confidence interval 0.58-0.73), and fairly good calibration. Conclusion: The evaluation of our multivariable prediction model in a large, clinically representative study population, proves that routine clinical and pathological variables are not suitable to select patients with LCNB-proven DCIS for SNB during primary surgery. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-14-03.
- Open Access
- 11 October 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (10) , e77826
Development and Evaluation of a Prediction Model for Underestimated Invasive Breast Cancer in Women with Ductal Carcinoma In Situ at Stereotactic Large Core Needle Biopsy
We aimed to develop a multivariable model for prediction of underestimated invasiveness in women with ductal carcinoma in situ at stereotactic large core needle biopsy, that can be used to select patients for sentinel node biopsy at primary surgery. From the literature, we selected potential preoperative predictors of underestimated invasive breast cancer. Data of patients with nonpalpable breast lesions who were diagnosed with ductal carcinoma in situ at stereotactic large core needle biopsy, drawn from the prospective COBRA (Core Biopsy after RAdiological localization) and COBRA2000 cohort studies, were used to fit the multivariable model and assess its overall performance, discrimination, and calibration. 348 women with large core needle biopsy-proven ductal carcinoma in situ were available for analysis. In 100 (28.7%) patients invasive carcinoma was found at subsequent surgery. Nine predictors were included in the model. In the multivariable analysis, the predictors with the strongest association were lesion size (OR 1.12 per cm, 95% CI 0.98-1.28), number of cores retrieved at biopsy (OR per core 0.87, 95% CI 0.75-1.01), presence of lobular cancerization (OR 5.29, 95% CI 1.25-26.77), and microinvasion (OR 3.75, 95% CI 1.42-9.87). The overall performance of the multivariable model was poor with an explained variation of 9% (Nagelkerke’s R2), mediocre discrimination with area under the receiver operating characteristic curve of 0.66 (95% confidence interval 0.58-0.73), and fairly good calibration. The evaluation of our multivariable prediction model in a large, clinically representative study population proves that routine clinical and pathological variables are not suitable to select patients with large core needle biopsy-proven ductal carcinoma in situ for sentinel node biopsy during primary surgery.
- 11 October 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (10) , e77826
Open AccessDevelopment and Evaluation of a Prediction Model for Underestimated Invasive Breast Cancer in Women with Ductal Carcinoma In Situ at Stereotactic Large Core Needle Biopsy
We aimed to develop a multivariable model for prediction of underestimated invasiveness in women with ductal carcinoma in situ at stereotactic large core needle biopsy, that can be used to select patients for sentinel node biopsy at primary surgery. From the literature, we selected potential preoperative predictors of underestimated invasive breast cancer. Data of patients with nonpalpable breast lesions who were diagnosed with ductal carcinoma in situ at stereotactic large core needle biopsy, drawn from the prospective COBRA (Core Biopsy after RAdiological localization) and COBRA2000 cohort studies, were used to fit the multivariable model and assess its overall performance, discrimination, and calibration. 348 women with large core needle biopsy-proven ductal carcinoma in situ were available for analysis. In 100 (28.7%) patients invasive carcinoma was found at subsequent surgery. Nine predictors were included in the model. In the multivariable analysis, the predictors with the strongest association were lesion size (OR 1.12 per cm, 95% CI 0.98-1.28), number of cores retrieved at biopsy (OR per core 0.87, 95% CI 0.75-1.01), presence of lobular cancerization (OR 5.29, 95% CI 1.25-26.77), and microinvasion (OR 3.75, 95% CI 1.42-9.87). The overall performance of the multivariable model was poor with an explained variation of 9% (Nagelkerke’s R2), mediocre discrimination with area under the receiver operating characteristic curve of 0.66 (95% confidence interval 0.58-0.73), and fairly good calibration. The evaluation of our multivariable prediction model in a large, clinically representative study population proves that routine clinical and pathological variables are not suitable to select patients with large core needle biopsy-proven ductal carcinoma in situ for sentinel node biopsy during primary surgery.
- 14 February 2012
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (4) , 1073-1081
Optical Imaging with Her2-Targeted Affibody Molecules Can Monitor Hsp90 Treatment Response in a Breast Cancer Xenograft Mouse Model
Purpose: To determine whether optical imaging can be used for in vivo therapy response monitoring as an alternative to radionuclide techniques. For this, we evaluated the known Her2 response to 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride (17-DMAG) treatment, an Hsp90 inhibitor. Experimental Design: After in vitro 17-DMAG treatment response evaluation of MCF7 parental cells and 2 HER2-transfected clones (clone A medium, B high Her2 expression), we established human breast cancer xenografts in nude mice (only parental and clone B) for in vivo evaluation. Mice received 120 mg/kg of 17-DMAG in 4 doses at 12-hour intervals intraperitonially (n = 14) or PBS as carrier control (n = 9). Optical images were obtained both pretreatment (day 0) and posttreatment (day 3, 6, and 9), always 5 hours postinjection of 500 pmol of anti-Her2 Affibody-AlexaFluor680 via tail vein (with preinjection background subtraction). Days 3 and 9 in vivo optical imaging signal was further correlated with ex vivo Her2 levels by Western blot after sacrifice. Results: Her2 expression decreased with 17-DMAG dose in vitro. In vivo optical imaging signal was reduced by 22.5% in clone B (P = 0.003) and by 9% in MCF7 parental tumors (P = 0.23) 3 days after 17-DMAG treatment; optical imaging signal recovered in both tumor types at days 6 to 9. In the carrier group, no signal reduction was observed. Pearson correlation of in vivo optical imaging signal with ex vivo Her2 levels ranged from 0.73 to 0.89. Conclusions: Optical imaging with an affibody can be used to noninvasively monitor changes in Her2 expression in vivo as a response to treatment with an Hsp90 inhibitor, with results similar to response measurements in positron emission tomography imaging studies. Clin Cancer Res; 18(4); 1073–81. ©2012 AACR.
- 14 February 2012
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (4) , 1073-1081
Optical Imaging with Her2-Targeted Affibody Molecules Can Monitor Hsp90 Treatment Response in a Breast Cancer Xenograft Mouse Model
Purpose: To determine whether optical imaging can be used for in vivo therapy response monitoring as an alternative to radionuclide techniques. For this, we evaluated the known Her2 response to 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride (17-DMAG) treatment, an Hsp90 inhibitor. Experimental Design: After in vitro 17-DMAG treatment response evaluation of MCF7 parental cells and 2 HER2-transfected clones (clone A medium, B high Her2 expression), we established human breast cancer xenografts in nude mice (only parental and clone B) for in vivo evaluation. Mice received 120 mg/kg of 17-DMAG in 4 doses at 12-hour intervals intraperitonially (n = 14) or PBS as carrier control (n = 9). Optical images were obtained both pretreatment (day 0) and posttreatment (day 3, 6, and 9), always 5 hours postinjection of 500 pmol of anti-Her2 Affibody-AlexaFluor680 via tail vein (with preinjection background subtraction). Days 3 and 9 in vivo optical imaging signal was further correlated with ex vivo Her2 levels by Western blot after sacrifice. Results: Her2 expression decreased with 17-DMAG dose in vitro. In vivo optical imaging signal was reduced by 22.5% in clone B (P = 0.003) and by 9% in MCF7 parental tumors (P = 0.23) 3 days after 17-DMAG treatment; optical imaging signal recovered in both tumor types at days 6 to 9. In the carrier group, no signal reduction was observed. Pearson correlation of in vivo optical imaging signal with ex vivo Her2 levels ranged from 0.73 to 0.89. Conclusions: Optical imaging with an affibody can be used to noninvasively monitor changes in Her2 expression in vivo as a response to treatment with an Hsp90 inhibitor, with results similar to response measurements in positron emission tomography imaging studies. Clin Cancer Res; 18(4); 1073–81. ©2012 AACR.
- Open Access
- 30 March 2011
- Published by Optica Publishing Group in Biomedical Optics Express
- Vol. 2 (4) , 1007-1020
Optical mammography combined with fluorescence imaging: lesion detection using scatterplots
Using scatterplots of 2 or 3 parameters, diffuse optical tomography and fluorescence imaging are combined to improve detectability of breast lesions. Small or low contrast phantom-lesions that were missed in the optical and fluorescence images were detected in the scatterplots. In patient measurements, all tumors were visible and easily differentiated from artifacts and areolas in the scatterplots. The different rate of intake and wash out of the fluorescent contrast agent in the healthy versus malignant tissues was also observed in the scatterplot: this information can be used to discriminate malignant lesion from normal structures.
- 30 March 2011
- Published by Optica Publishing Group in Biomedical Optics Express
- Vol. 2 (4) , 1007-1020
Open AccessOptical mammography combined with fluorescence imaging: lesion detection using scatterplots
Using scatterplots of 2 or 3 parameters, diffuse optical tomography and fluorescence imaging are combined to improve detectability of breast lesions. Small or low contrast phantom-lesions that were missed in the optical and fluorescence images were detected in the scatterplots. In patient measurements, all tumors were visible and easily differentiated from artifacts and areolas in the scatterplots. The different rate of intake and wash out of the fluorescent contrast agent in the healthy versus malignant tissues was also observed in the scatterplot: this information can be used to discriminate malignant lesion from normal structures.